NRIX
NASDAQNurix Therapeutics Inc.
News · 26 weeks60+13%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- Other8(30%)
- SEC Filings4(15%)
- Leadership2(7%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- PRNurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources OfficerBRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO). Mr. Burwell will serve as a member of the company’s Executive Management Team and will lead Nurix's human resources organization as the company advances its late-stage clinical pipeline and prepares for commercialization while maintaining its leadership position in targeted protein degradation drug discovery research. "Nurix is entering a new chapter as we evolve
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
- SECSEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
- INSIDERChief Scientific Officer Hansen Gwenn exercised 4,356 shares at a strike of $1.86 and sold $108,900 worth of shares (4,356 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Scientific Officer Hansen Gwenn sold $100,142 worth of shares (4,111 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 117,227 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Financial Officer Van Houte Hans sold $115,989 worth of shares (4,761 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 40,166 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- PRNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderOral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following
- PRNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaBRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating bexobrutideg, a potential best-in-class targeted protein degrader of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received a covalent BTK inhibitor. The global study is being conducted under the collaboration between Nurix and Roche and marks the first Phase 3 trial for bexobrutideg. The registrational study is designed to demonstrate the superiority of bexobrutideg v
- INSIDERChief Legal Officer Ring Christine exercised 5,787 shares at a strike of $8.72 and sold $382,358 worth of shares (16,589 units at $23.05) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 9,110 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Financial Officer Van Houte Hans converted options into 10,180 shares and sold $66,524 worth of shares (2,845 units at $23.38), increasing direct ownership by 20% to 44,927 units (SEC Form 4) (withholding obligation)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine converted options into 10,180 shares and sold $89,954 worth of shares (3,847 units at $23.38), increasing direct ownership by 47% to 19,912 units (SEC Form 4) (tax liability)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Scientific Officer Hansen Gwenn converted options into 10,180 shares and sold $89,954 worth of shares (3,847 units at $23.38), increasing direct ownership by 6% to 121,338 units (SEC Form 4) (withholding obligation)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- PRNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyBRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Summary of Business TermsUnder the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential t
- SECSEC Form 10-Q filed by Nurix Therapeutics Inc.10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
- SECNurix Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
- PRNurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateEntered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as a best-in-class BTK degrader across multiple lines of therapy in CLL Well capitalized with cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and pro-forma cash
- PRA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas
- INSIDERChief Legal Officer Ring Christine exercised 11,008 shares at a strike of $5.47 and sold $259,366 worth of shares (11,008 units at $23.56) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- ANALYSTOppenheimer resumed coverage on Nurix Therapeutics with a new price targetOppenheimer resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $28.00
- INSIDERChief Scientific Officer Hansen Gwenn sold $107,880 worth of shares (5,394 units at $20.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 115,005 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine exercised 28,935 shares at a strike of $8.05 and sold $580,506 worth of shares (28,935 units at $20.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SECNurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
- PRNurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of TherapyHigh objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June
- SECNurix Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
- PRRoche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyAgreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of
NRIX FAQ
7 questionsWhat does Nurix Therapeutics Inc. do?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma...Where does NRIX stock trade?
Nurix Therapeutics Inc. (NRIX) is listed on NASDAQ.What sector and industry is NRIX in?
Nurix Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nurix Therapeutics Inc. go public?
Nurix Therapeutics Inc. (NRIX) completed its IPO in 2020.What are analysts saying about NRIX?
Nurix Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $2800.00 price target on 2026-06-29. Recent price targets range from $1600.00 to $3600.00.What companies are similar to NRIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NRIX side-by-side with any of them on Quantisnow.How can I track NRIX on Quantisnow?
Quantisnow aggregates Nurix Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRIX to receive live email and push alerts on every new disclosure.